Healios K.K.
OTC: HLOSF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Tadahisa S. Kagimoto
- Employees
- 65
- Headquarters
- Tokyo, Japan
- IPO year
- 2020
- Market cap
- $193.8M
- Website
- https://www.healios.co.jp
Loading HLOSF…
Loading profile data…Frequently asked questions about HLOSF
What does Healios K.K. (HLOSF) do?
Healios K.K. is a biotechnology firm specializing in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products, with operations spanning Japan, Europe, and the United States. The company's robust pipeline features several advanced cellular and tissue-based therapies: iPSC-derived regenerati...
Where does HLOSF trade?
Healios K.K. (HLOSF) trades on the Other OTC.
What sector is HLOSF in?
Healios K.K. (HLOSF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Healios K.K.?
Tadahisa S. Kagimoto is the chief executive officer of Healios K.K. (HLOSF).
Where is Healios K.K. headquartered?
Healios K.K. is headquartered in Japan.
Does HLOSF pay a dividend?
Healios K.K. (HLOSF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HLOSF go public?
Healios K.K. (HLOSF) completed its initial public offering in 2020.